Treating Schizophrenia
Long-acting injectable (LAI) antipsychotic formulations are being considered more often in the treatment of schizophrenia to promote medication adherence. Genoa Healthcare recently hosted a webinar providing an update on available LAIs and addressing potential reasons for starting patients on the medications. Can Genoa help your clinic and consumers with LAIs?
Click here to review general clinical considerations and pearls regarding the long-acting injectable antipsychotics available.
The webinar also addressed recent COVID-19 developments, including updates on the Omicron variant and new oral antiviral medications.
- Learn more about the Omicron Variant and frequently asked questions surrounding COVID-19 here.
- Review Pfizer-BioNTech COVID-19 vaccine product presentations here.
Watch the recording below:
To learn more about how Genoa can help you and those you serve, contact us today.
